Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04491721 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT04491721 · ClinicalTrials.gov record · last posted 2020-07-29

Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL

Name: Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL — clinical trial record (NCT04491721)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusEnrolling by Invitation

PhaseNot specified

SponsorChinese Academy of Medical Sciences

Started2020-07

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The main objective of this study is to observe the overall survival of Rituximab Biosimilar HLX01 and MabThera in Combination With CHOP, in previously untreated subjects with CD20+ DLBCL. The secondary objective of this study is to observe the progression-free survival of Rituximab Biosimilar HLX01 and MabThera in Combination With CHOP, in previously untreated subjects with CD20+ DLBCL.

Trial Details

NCT Number	NCT04491721
Lead Sponsor	Chinese Academy of Medical Sciences
Conditions	Diffuse Large B Cell Lymphoma
Enrollment	407 participants
Start Date	2020-07
Primary Completion	2027-06 (estimated)
Study Completion	2027-07 (estimated)
Updated on ClinicalTrials.gov	2020-07-29